Belvedere Trading
ABUS icon

Belvedere Trading’s Arbutus Biopharma ABUS Stock Holding History

Belvedere Trading’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,721
Closed -$51.6K – 729
2025
Q4 		$51.6K Buy
+10,721
New +$48.2K ﹤0.01% 656
2022
Q1 		– Sell
-17,579
Closed -$47K – 447
2021
Q4 		$47K Sell
17,579
-16,126
-48% -$62.6K ﹤0.01% 366
2021
Q3 		$140K Buy
+33,705
New +$112K ﹤0.01% 304

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Belvedere Trading's ABUS Position: Q1 2026 in Review

Belvedere Trading sold out of Arbutus Biopharma (ABUS) in Q1 2026, closing a stake of 10,721 shares — an estimated $51.6K sold.

Belvedere Trading first reported a position in ABUS in Q3 2021 and held it in 3 quarters. The position peaked at $140K in Q3 2021. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

  • Belvedere Trading reported no remaining Arbutus Biopharma position as of Q1 2026 after selling out during the quarter.
  • Belvedere Trading sold 10,721 Arbutus Biopharma shares in Q1 2026, an estimated $51.6K.
  • Belvedere Trading first reported a position in Arbutus Biopharma in Q3 2021 and held it in 3 quarters.
  • Belvedere Trading's Arbutus Biopharma position peaked at $140K in Q3 2021.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on Belvedere Trading's 13F filing for Q1 2026, filed 12 May 2026.